The significant reduction in the price target for PTC Therapeutics by RBC Capital could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price. The 'Sector Perform' rating suggests that the stock is expected to perform in line with the sector, but the lowered price target indicates a less optimistic outlook.